Showing Results for: “Contact ”

Safe at School: North Carolina

When you get sick with things like colds or the flu, the illness and stress from it causes your body to release hormones that raise blood glucose (blood sugar) levels, making it harder to keep your blood glucose in your target range.

Linagliptin, when added to usual diabetes care in people with type 2 diabetes (T2D) with increased risk of cardiovascular (CV) and/or renal disease, resulted in incidences of CV and renal events comparable to placebo over a median period of 2.2 years across a broad range of age and kidney function status, according to a symposium presentation today titled “Linagliptin Trial in Type 2 Diabetes Mellitus at High Cardiovascular Risk with Chronic Kidney Disease,” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco

Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care The iLet bionic pancreas (BP)¹ significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy of either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), according to the study, “First Human Study Testing the iLet, a Purpose-Built Bionic Pancreas Platform,” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone

In recent years, diabetes technology has evolved at a rapid pace, and the use of insulin pumps and continuous glucose monitoring (CGM) systems has grown tremendously. To foster a more active role in diabetes management among youth, professionals encourage consistent utilization of monitoring tools across multiple environments. A professional interest group presentation entitled “Diabetes Technology Use in Schools, Camps, and Emergency Rooms,” focused on the use of diabetes technology for children and adolescents in a variety of settings, today at the American Diabetes Association’s® (ADA’s)

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now report on the extensive development of severe renal, cardiac, eye, nerve, and pregnancy complications in early adulthood in patients with youth-onset type 2 diabetes. Results from this follow up study, TODAY2, presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®, show an accelerating rate of serious complications within the last five years and point to the increased

New research shows that daily oral vitamin D supplementation does not effectively reduce the risk of type 2 diabetes among vitamin D-sufficient adults at high risk for developing the disease, according to the “The Vitamin D and Type 2 Diabetes (D2d) Study – A Multicenter Randomized Controlled Trial for Diabetes Prevention” study presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. More than 84 million Americans have prediabetes, which is a precursor of symptoms indicating higher risk of progression to type

American Heart Association ® and American Diabetes Association ® reveal results of Know Diabetes by Heart ™ survey and share practical tips for staying on track with health goals through the holiday season Nearly half (49%) of people living with type 2 diabetes said managing their condition during a typical fall and winter holiday season is more difficult than other times of the year, according to a new survey for the American Heart Association and American Diabetes Association. The online survey of more than 1,000 U.S. adults 45 and older completed by real-time market research platform

Results from four clinical studies identify potential new treatment option for people with type 2 diabetes Data from the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide, a novel investigational once-weekly medication for the treatment of type 2 diabetes, demonstrates statistically significant A1C and weight reductions versus several comparators. Findings of global registration trials, SURPASS-1, SURPASS-2, SURPASS-3, and SURPASS-5 were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). The SURPASS-1 study was be

Latest CDC and NIDDK sponsored SEARCH for Diabetes in Youth research indicates substantial percentage of today’s youth with diabetes are not meeting recommended A1C goals Despite the increased availability of diabetes technology, new therapies and more aggressive glycemic targets, today’s youth and young adults with diabetes in the United States are not demonstrating improved glycemic control compared to their counterparts from years past. Most notably, many age groups have worse glycemic control compared to youth and young adults from 2002-2007. Researchers revealed these data today at the